Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Current Oncology Reports
Published in: Current Oncology Reports 3/2019

01-03-2019 | Sinonasal Carcinoma | Head and Neck Cancers (EY Hanna, Section Editor)

Sinonasal Undifferentiated Carcinoma

Authors: Ahmed S. Abdelmeguid, Diana Bell, Ehab Y. Hanna

Published in: Current Oncology Reports | Issue 3/2019

Login to get access

Abstract

Purpose of Review

To provide a comprehensive review of the literature highlighting the recent advances in the diagnosis and management of sinonasal undifferentiated carcinoma (SNUC)

Recent Findings

SNUC usually presents at advanced stage and the prognosis is usually poor with high rates of locoregional recurrence and tendency to metastasize. Special attention should be made in differentiating SNUC from other sinonasal malignancies in order to guide the appropriate treatment accordingly. Multimodality treatment is usually recommended for treating SNUC. The use of neoadjuvant chemotherapy may be associated with improved outcome and can be used to guide the subsequent treatment selection.

Summary

Despite the recent advances in chemotherapeutic agents, radiation techniques, and surgical approaches, the prognosis and survival outcomes of SNUC remain poor. The addition of induction chemotherapy to the treatment approach followed by definitive local therapy needs to be further studied as it might improve the outcome.
Literature
1.
Frierson HF Jr, Mills SE, Fechner RE, Taxy JB, Levine PA. Sinonasal undifferentiated carcinoma: an aggressive neoplasm derived from Schneiderian epithelium and distinct from olfactory neuroblastoma. Am J Surg Pathol. 1986;10(11):771–2.CrossRefPubMed
2.
Ejaz A, Wenig BM. Sinonasal undifferentiated carcinoma: clinical and pathologic features and a discussion on classification, cellular differentiation, and differential diagnosis. Adv Anat Pathol. 2005;12(3):134–43.CrossRefPubMed
3.
Mendenhall WM, Mendenhall CM, Riggs CE Jr, Villaret DB, Mendenhall NP. Sinonasal undifferentiated carcinoma. Am J Clin Oncol. 2006;29(1):27–31.CrossRefPubMed
4.
Rischin D, Porceddu S, Peters L, Martin J, Corry J, Weih L. Promising results with chemoradiation in patients with sinonasal undifferentiated carcinoma. Head Neck. 2004;26(5):435–41.CrossRefPubMed
5.
6.
Gray ST, Herr MW, Sethi RK, Diercks G, Lee L, Curry W, et al. Treatment outcomes and prognostic factors, including human papillomavirus, for sinonasal undifferentiated carcinoma: a retrospective review. Head Neck. 2015;37(3):366–74.CrossRefPubMed
7.
Musy PY, Reibel JF, Levine PA. Sinonasal undifferentiated carcinoma: the search for a better outcome. Laryngoscope. 2002;112(8):1450–5.CrossRefPubMed
8.
Tanzler ED, Morris CG, Orlando CA, Werning JW, Mendenhall WM. Management of sinonasal undifferentiated carcinoma. Head Neck. 2008;30(5):595–9.CrossRefPubMed
9.
Enepekides DJ. Sinonasal undifferentiated carcinoma: an update. Curr Opin Otolaryngol Head Neck Surg. 2005;13(4):222–5.CrossRefPubMed
10.
Thompson LDR, Bell D, Bishop JA. Neuroendocrine carcinomas. In: El-Naggar AK, Chan JKC, Grandis JR, Takata T, Slootweg P, editors. Pathology and genetics of head and neck tumours. Lyon: IARC Press; 2017. p. 21–3.
11.
Bell D, Franchi A, Gillison M, Thompson LDR, Wenig BM. Olfactory neuroblastoma. In: El Naggar AK, JKC C, Grandis JR, Takata T, Slootweg P, editors. Pathology and genetics of head and neck tumours. Lyon: IARC Press; 2017. p. 57–9.
12.
Bell D, Hanna EY. Sinonasal undifferentiated carcinoma: morphological heterogeneity, diagnosis, management and biological markers. Expert Rev Anticancer Ther. 2013;13(3):285–96.CrossRefPubMed
13.
López-Hernández A, Vivanco B, Franchi A, Bloemena E, Cabal VN, Potes S, et al. Genetic profiling of poorly differentiated sinonasal tumours. Sci Rep. 2018;8(1):3998.CrossRefPubMedPubMedCentral
14.
Cerilli LA, Holst VA, Brandwein MS, Stoler MH, Mills SE. Sinonasal undifferentiated carcinoma: immunohistochemical profile and lack of EBV association. Am J Surg Pathol. 2001;25(2):156–63.CrossRefPubMed
15.
Bell D, Hanna EY, Weber RS, De Monte F, Triantafyllou A, Lewis JS, et al. Neuroendocrine neoplasms of the sinonasal region. Head & Neck. 2015.
16.
Wenig BM. Undifferentiated malignant neoplasms of the sinonasal tract. Arch Pathol Lab Med. 2009;133(5):699–712.PubMed
17.
18.
Franchi A, Miligi L, Palomba A, Giovannetti L, Santucci M. Sinonasal carcinomas: recent advances in molecular and phenotypic characterization and their clinical implications. Crit Rev Oncol Hematol. 2011;79(3):265–77.CrossRefPubMed
19.
Franchi A, Moroni M, Massi D, Paglierani M, Santucci M. Sinonasal undifferentiated carcinoma, nasopharyngeal-type undifferentiated carcinoma, and keratinizing and nonkeratinizing squamous cell carcinoma express different cytokeratin patterns. Am J Surg Pathol. 2002;26(12):1597–604.CrossRefPubMed
20.
Wadsworth B, Bumpous JM, Martin AW, Nowacki MR, Jenson AB, Farghaly H. Expression of p16 in sinonasal undifferentiated carcinoma (SNUC) without associated human papillomavirus (HPV). Head Neck Pathol. 2011;5(4):349–54.CrossRefPubMedPubMedCentral
21.
Gil Z, Orr-Urtreger A, Voskoboinik N, Trejo-Leider L, Spektor S, Shomrat R, et al. Cytogenetic analysis of sinonasal carcinomas. Otolaryngol Head Neck Surg. 2006;134(4):654–60.CrossRefPubMed
22.
Takahashi Y, Kupferman ME, Bell D, Jiffar T, Lee JG, Xie T-X, et al. Establishment and characterization of novel cell lines from sinonasal undifferentiated carcinoma. Clin Cancer Res. 2012;18(22):6178–87.CrossRefPubMedPubMedCentral
23.
24.
Agaimy A, Koch M, Lell M, Semrau S, Dudek W, Wachter DL, et al. SMARCB1(INI1)-deficient sinonasal basaloid carcinoma: a novel member of the expanding family of SMARCB1-deficient neoplasms. Am J Surg Pathol. 2014;38:1274–81.CrossRefPubMedPubMedCentral
25.
Bell DHE, Agaimy A, Weissferdt A. Reappraisal of sinonasal undifferentiated carcinoma: SMARCB1 (INI1)-deficient sinonasal carcinoma: a single-institution experience. Virchows Arch. 2015;467(6):649–56.CrossRefPubMed
26.
Lewis J, Bishop JA, Gillisson M, Westra WH, Yarborough WG. Sinonasal undifferentiated carcinoma. In: El-Naggar AK, JKC C, Grandis JR, Takata T, Slootweg P, editors. Pathology and genetics of head and neck tumours. Lyon: IARC Press; 2017. p. 18–20.
27.
28.
Rosenthal DI, Barker JL, El-Naggar AK, Glisson BS, Kies MS, Diaz EM, et al. Sinonasal malignancies with neuroendocrine differentiation. Cancer. 2004;101(11):2567–73.CrossRefPubMed
29.
Chen AM, Daly ME, El-Sayed I, Garcia J, Lee NY, Bucci MK, et al. Patterns of failure after combined-modality approaches incorporating radiotherapy for sinonasal undifferentiated carcinoma of the head and neck. Int J Radiat Oncol Biol Phys. 2008;70(2):338–43.CrossRefPubMed
30.
Lin EM, Sparano A, Spalding A, Eisbruch A, Worden FP, Heth J, et al. Sinonasal undifferentiated carcinoma: a 13-year experience at a single institution. Skull Base. 2010;20(02):061–7.CrossRef
31.
Al-Mamgani A, van Rooij P, Mehilal R, Tans L, Levendag PC. Combined-modality treatment improved outcome in sinonasal undifferentiated carcinoma: single-institutional experience of 21 patients and review of the literature. Eur Arch Otorhinolaryngol. 2013;270(1):293–9.CrossRefPubMed
32.
Mourad WF, Hauerstock D, Shourbaji RA, Hu KS, Culliney B, Li Z, et al. Trimodality management of sinonasal undifferentiated carcinoma and review of the literature. Am J Clin Oncol. 2013;36(6):584–8.CrossRefPubMed
33.
van der Laan TP, Bij HP, van Hemel BM, Plaat BE, Wedman J, van der Laan BF, et al. The importance of multimodality therapy in the treatment of sinonasal neuroendocrine carcinoma. Eur Arch Otorhinolaryngol. 2013;270(9):2565–8.CrossRefPubMed
34.
• Chambers KJ, Lehmann AE, Remenschneider A, Dedmon M, Meier J, Gray ST, et al. Incidence and survival patterns of sinonasal undifferentiated carcinoma in the United States. J Neurol Surg B Skull Base. 2015;76(02):094–100 Large National Cancer Institute’s Surveillance Epidemiology and End Results data that included 318 SNUCs. They found a survival benefit of surgery and radiation therapy with a trend toward improved survival in recent years.
35.
• de Bonnecaze G, Verillaud B, Chaltiel L, Fierens S, Chapelier M, Rumeau C, et al. Clinical characteristics and prognostic factors of sinonasal undifferentiated carcinoma: a multicenter study. Int Forum Allergy Rhinol. 2018;8(9):1065–72 A larger multicenter collabrative study evaluating the treatment outcomes and prognostic factors of SNUC. Overall, multimodal therapies including induction chemotherapy and intensity-modulated radiotherapy may improve the prognosis of SNUC. CrossRefPubMed
36.
37.
Fried D, Zanation AM, Huang B, Hayes N, Morris DE, Rosenman J, et al. Management of nonesthesioneuroblastoma sinonasal malignancies with neuroendocrine differentiation. Laryngoscope. 2012;122(10):2210–5.CrossRefPubMed
38.
Kim BS, Vongtama R, Juillard G. Sinonasal undifferentiated carcinoma: case series and literature review. Am J Otolaryngol. 2004;25(3):162–6.CrossRefPubMed
39.
Rischin D, Coleman A. Sinonasal malignancies of neuroendocrine origin. Hematol Oncol Clin North Am. 2008;22(6):1297–316.CrossRefPubMed
40.
• Amit M, Abdelmeguid AS, Watcherporn T, Tam S, Bell D, Ferrarotto R, Glisson B, et al. Induction chemotherapy response as a guide for treatment optimization in sinonasal undifferentiated carcinoma. J Clin Oncol. 2019;37(6):504–12. The largest retrospective study in the literature from a single institution describing the use of induction chemotherapy to guide the subsequent treatment selection in SNUC based on the response.
41.
Takahashi Y, Lee J, Pickering C, Bell D, Jiffar TW, Myers JN, et al. Human epidermal growth factor receptor 2/neu as a novel therapeutic target in sinonasal undifferentiated carcinoma. Head Neck. 2016;38:E1926–34.CrossRefPubMedPubMedCentral
Metadata
Title
Sinonasal Undifferentiated Carcinoma
Authors
Ahmed S. Abdelmeguid
Diana Bell
Ehab Y. Hanna
Publication date
01-03-2019
Publisher
Springer US
Published in
Current Oncology Reports / Issue 3/2019
Print ISSN: 1523-3790
Electronic ISSN: 1534-6269
DOI
https://doi.org/10.1007/s11912-019-0776-4

Other articles of this Issue 3/2019

Current Oncology Reports 3/2019 Go to the issue

Cardio-oncology (EH Yang, Section Editor)

Cardiac Complications in the Adult Bone Marrow Transplant Patient

Lymphomas (MR Smith, Section Editor)

How Recent Advances in Biology of Waldenström’s Macroglobulinemia May Affect Therapy Strategy

Genitourinary Cancers (DP Petrylak and JW Kim, Section Editors)

Management of Adrenocortical Carcinoma

Genitourinary Cancers (DP Petrylak and JW Kim, Section Editors)

Clinical and Genomic Considerations for Variant Histology in Bladder Cancer

Lung Cancer (H Borghaei, Section Editor)

Emerging Targeted Therapies for the Treatment of Non-small Cell Lung Cancer

Breast Cancer (B Overmoyer, Section Editor)

CDK 4/6 Inhibitors in Breast Cancer: Current Controversies and Future Directions
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits